Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: A report from the Israel penn international transplant tumor registry

Transplantation

Volumn 78, Issue 11, 2004, Pages 1676-1682

  Aull, Meredith J ^a   Buell, Joseph F ^b   Trofe, Jennifer ^b   First, M Roy ^c   Alloway, Rita R ^b   Hanaway, Michael J ^b   Wagoner, Lynne ^d   Gross, Thomas G ^e   Beebe, Thomas ^b   Woodle, E Steve ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Cardiac; Heart; Lymphoproliferative disease; Malignancy; Outcome

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; CAUSE OF DEATH; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; ISRAEL; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; REGISTER; RISK ASSESSMENT; SHOCK; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; REGISTRIES;

EID: 10644249812     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000144333.19106.58     Document Type: Article

References (23)

1. Mihalov ML, Gattuso P, Abraham K, et al. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10: 248.
2. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101.
3. Couetil JP, McGoldrick JP, Wallwork J, et al. Malignant tumors after heart transplantation. J Heart Transplant 1990; 9: 622.
4. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Eight-year results of cyclosporine-treated patients with cardiac transplants. J Thorac Cardiovasc Surg 1990; 99: 500.
5. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877.
6. Rinde-Hoffman D, Cintron GB, Ferguson JE, et al. Lymphoproliferative disorder early after cardiac transplantation. Am J Cardiology 1991; 68: 1724.
7. Chen JM, Barr ML, Chadburn A, et al. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993; 56: 527.
8. Hsieh WS, Lemas MV, Ambinder RF. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease. Transpl Infect Dis 1999; 1: 204.
9. 2000 Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1990-1999. U.S. Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA.
10. Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients. Transplantation 1982; 33: 347.
11. Trofe J, Buell JF, Hanaway MJ, et al. Post-transplant lymphoproliferative disorder in kidney transplantation: a 32-year experience in 405 patients from the Israel Penn International Transplant Tumor Registry [abstract]. Am J Transplantation 2001; 1: 376.
12. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.
13. Swinnen LJ, Fisher SG, Fisher RI, et al. Elimination of OKT3 induction therapy: impact on the incidence of lymphoma following cardiac transplantation [abstract]. J Heart Lung Transplant 1994; 13: S68, abstract 148.
14. Ratkovec RM, O'Connell JB, Bristow MR, et al. Post-transplant lymphoproliferative disease in cardiac transplant patients receiving OKT3 therapy. Clin Transplant 1992; 6: 260.
15. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In Terasaki PI (ed) Clinical Transplants 1990. UCLA Tissue Typing Laboratory, pp. 53-62, 1991.
16. Anderson P, Schroeder TJ, Hariharan S, et al. Incidence of posttransplant lymphoproliferative disease in OKT3-treated renal transplant recipients. Clin Transplant 1993; 7: 582.
17. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23: 1106.
18. First MR, Peddi VR. Malignancies complicating organ transplantation. Transplant Proc 1998; 30: 2768.
19. Chaparro S, Gao S, Perlroth M, et al. Posttransplantation lymphoproliferative disease in heart and heart-lung transplant recipients: thirty years experience at our hospital [abstract]. J Heart Lung Transplant 2001; 20: 258.
20. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for post-cardiac transplant lymphoproliferation. Blood 1995; 86: 3333.
21. Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001; 20: 770.
22. Verschuuren EAM, Stevens SJC, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73: 100.
23. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11(Suppl 1):113.